FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890738265> ?p ?o ?g. }

• W2890738265 endingPage "25" @default.
• W2890738265 startingPage "19" @default.
• W2890738265 abstract "Background Active illicit drug use can present a barrier to the medical management of HIV infection by complicating adherence to antiretroviral therapy (ART). Plasma HIV-1 RNA viral load (VL) rebound, defined as a period of detectable HIV VL following ART and VL suppression, can lead to the generation of viral resistance and potential treatment failure. We sought to investigate the contribution of substance use patterns on rates of VL rebound. Methods We used data from the ACCESS study, a long-running community-recruited prospective cohort of HIV-positive people who use illicit drugs in Vancouver, Canada, a setting of universal no-cost HIV treatment. We analysed time to VL rebound (that is, two consecutive observations ≥1,000 copies/ml) after ART initiation and sustained viral suppression (that is, two consecutive observations <50 copies/ml) using extended Cox regression models with a recurrent events framework. Results Between May 1996 and November 2013, 564 ART-exposed participants achieved at least one instance of VL suppression and contributed 1,893.8 person-years of observation. Over follow-up, 198 (35.1%) participants experienced ≥ one instance of VL rebound. In adjusted analyses, VL rebound was associated with younger age (adjusted hazard ratio [AHR] =0.97, 95% CI: 0.95, 0.98), heroin injection (≥ daily versus < daily, AHR =1.52, 95% CI: 1.01, 2.30), crack use (≥ daily versus < daily, AHR = 1.73, 95% CI: 1.08, 1.92) and heavy alcohol use (≥ four versus < four drinks/day, AHR =1.97, 95% CI: 1.17, 3.31). Conclusions The present study suggests that in addition to heavy alcohol use, high-intensity illicit drug use, particularly ≥ daily heroin injection and ≥ daily crack smoking are risk factors for VL rebound. In addition to the impact of high-intensity drug use on health-care engagement and ART adherence, some evidence exists on the direct impact of psychoactive substances on ART metabolism and the natural progression of HIV disease. At-risk individuals should be provided additional supports to preserve virological control and maintain the benefits of ART." @default.
• W2890738265 created "2018-09-27" @default.
• W2890738265 creator A5013162815 @default.
• W2890738265 creator A5030246925 @default.
• W2890738265 creator A5041290896 @default.
• W2890738265 creator A5048009605 @default.
• W2890738265 creator A5050662064 @default.
• W2890738265 creator A5061043962 @default.
• W2890738265 creator A5073679067 @default.
• W2890738265 creator A5079981787 @default.
• W2890738265 date "2019-01-01" @default.
• W2890738265 modified "2023-10-16" @default.
• W2890738265 title "Substance use Patterns and HIV-1 RNA Viral Load Rebound among HIV-Positive Illicit Drug users in a Canadian Setting" @default.
• W2890738265 cites W134303223 @default.
• W2890738265 cites W1496968467 @default.
• W2890738265 cites W1964622370 @default.
• W2890738265 cites W1967967289 @default.
• W2890738265 cites W1980050043 @default.
• W2890738265 cites W1985667653 @default.
• W2890738265 cites W1986775524 @default.
• W2890738265 cites W1987625732 @default.
• W2890738265 cites W1992620115 @default.
• W2890738265 cites W1998922421 @default.
• W2890738265 cites W2004755229 @default.
• W2890738265 cites W2005312953 @default.
• W2890738265 cites W2007452261 @default.
• W2890738265 cites W2011344872 @default.
• W2890738265 cites W2021847155 @default.
• W2890738265 cites W2025722763 @default.
• W2890738265 cites W2034185625 @default.
• W2890738265 cites W2035292650 @default.
• W2890738265 cites W2038342867 @default.
• W2890738265 cites W2042258507 @default.
• W2890738265 cites W2046465389 @default.
• W2890738265 cites W2051504717 @default.
• W2890738265 cites W2063649408 @default.
• W2890738265 cites W2067723545 @default.
• W2890738265 cites W2072694914 @default.
• W2890738265 cites W2074210574 @default.
• W2890738265 cites W2078585226 @default.
• W2890738265 cites W2079245949 @default.
• W2890738265 cites W2085981430 @default.
• W2890738265 cites W2107334477 @default.
• W2890738265 cites W2126608268 @default.
• W2890738265 cites W2140150768 @default.
• W2890738265 cites W2142554331 @default.
• W2890738265 cites W2153750288 @default.
• W2890738265 cites W2161800520 @default.
• W2890738265 cites W2166084084 @default.
• W2890738265 cites W2499821260 @default.
• W2890738265 cites W4597097 @default.
• W2890738265 doi "https://doi.org/10.3851/imp3265" @default.
• W2890738265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6455806" @default.
• W2890738265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30230474" @default.
• W2890738265 hasPublicationYear "2019" @default.
• W2890738265 type Work @default.
• W2890738265 sameAs 2890738265 @default.
• W2890738265 citedByCount "20" @default.
• W2890738265 countsByYear W28907382652019 @default.
• W2890738265 countsByYear W28907382652020 @default.
• W2890738265 countsByYear W28907382652021 @default.
• W2890738265 countsByYear W28907382652022 @default.
• W2890738265 countsByYear W28907382652023 @default.
• W2890738265 crossrefType "journal-article" @default.
• W2890738265 hasAuthorship W2890738265A5013162815 @default.
• W2890738265 hasAuthorship W2890738265A5030246925 @default.
• W2890738265 hasAuthorship W2890738265A5041290896 @default.
• W2890738265 hasAuthorship W2890738265A5048009605 @default.
• W2890738265 hasAuthorship W2890738265A5050662064 @default.
• W2890738265 hasAuthorship W2890738265A5061043962 @default.
• W2890738265 hasAuthorship W2890738265A5073679067 @default.
• W2890738265 hasAuthorship W2890738265A5079981787 @default.
• W2890738265 hasBestOaLocation W28907382652 @default.
• W2890738265 hasConcept C126322002 @default.
• W2890738265 hasConcept C142462285 @default.
• W2890738265 hasConcept C188816634 @default.
• W2890738265 hasConcept C201903717 @default.
• W2890738265 hasConcept C203014093 @default.
• W2890738265 hasConcept C205545832 @default.
• W2890738265 hasConcept C207103383 @default.
• W2890738265 hasConcept C3013748606 @default.
• W2890738265 hasConcept C44249647 @default.
• W2890738265 hasConcept C50382708 @default.
• W2890738265 hasConcept C71924100 @default.
• W2890738265 hasConcept C72563966 @default.
• W2890738265 hasConceptScore W2890738265C126322002 @default.
• W2890738265 hasConceptScore W2890738265C142462285 @default.
• W2890738265 hasConceptScore W2890738265C188816634 @default.
• W2890738265 hasConceptScore W2890738265C201903717 @default.
• W2890738265 hasConceptScore W2890738265C203014093 @default.
• W2890738265 hasConceptScore W2890738265C205545832 @default.
• W2890738265 hasConceptScore W2890738265C207103383 @default.
• W2890738265 hasConceptScore W2890738265C3013748606 @default.
• W2890738265 hasConceptScore W2890738265C44249647 @default.
• W2890738265 hasConceptScore W2890738265C50382708 @default.
• W2890738265 hasConceptScore W2890738265C71924100 @default.
• W2890738265 hasConceptScore W2890738265C72563966 @default.
• W2890738265 hasIssue "1" @default.

• next